Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: The aquitaine cohort, 1996-1997

American Journal of Epidemiology

Volumn 153, Issue 4, 2001, Pages 386-393

  Binquet, C ^a   Chêne, Geneviève ^a   Jacqmin Gadda, H ^a   Journot, V ^a   Saves M ^a   Lacoste, D ^b,c,h   Dabis, F ^a,h   Marimoutou, C ^h   Chene G ^h   Salamon, R ^h   Malvy, D ^c,h   Mercie P ^c,h   Pellegrin, I ^c,h   Dupon, M ^c,h   Moreau, J F ^c,h   Morlat, P ^c,h   Pellegrin, J L ^c,h   Ragnaud, J M ^c,h   Beylot, J ^c   Bernard, N ^c   Nouts, C ^c   Beylot, C ^c   Doutre, M S ^c   Conri, C ^c   Constans, J ^c   Couzigou, P ^c   Fleury, H ^c   Geniaux M ^c   Simon, A ^c   Lacut, J Y ^c   Cazorla, C ^c   Leng, B ^c   Le Bras, M ^c   Djossou, F ^c   Pivetaud, J P ^c   Taupin, J L ^c   De La Taille, C ^c   Dutronc, H ^c   Neau, D ^c   Series C ^c   Taytard, A ^c   Loste, M ^d   Blanchard, I ^d   Bonnal, F ^e   Blanchard, Y ^e   Farbos, S ^e   Gemain, M C ^e   Ceccaldi, J ^f   Jacquelin, X ^f   Buy, E ^g   Brossard, G ^g   Blaizeau, M J ^h   Decoin, M ^h   Dequae Merchadou, L ^h   Formaggio, A M ^h   Pontgahet, M ^h   Touchard, D ^h   Palmer, G ^h   more..

^a INSERM   (France)

^b HÔPITAL PELLEGRIN   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Dax Hospital   (France)

^e Bayonne Medical Center   (United States)

^f Libourne Hospital   (France)

^g Villeneuve sur Lot Hospital   (Italy)

^h NONE

Author keywords

Acquired immunodeficiency syndrome; Antiviral agents; CD4 positive T lymphocytes; Cell count; Immune system; Immunity; Opportunistic infections; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CANDIDIASIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; STATISTICAL MODEL; T LYMPHOCYTE; TOXOPLASMOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL PROTOCOLS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RISK FACTORS; TIME FACTORS;

EID: 0035865722     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/153.4.386     Document Type: Article

References (41)

1. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimiter or less
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
5. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
6. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
7. 6 cells/1 following combination antiretroviral therapy including protease inhibitors
8. Changes in CD4+ cell count and the risk of opportunistic infections or death after highly active antiretroviral treatment
9. Risk of new AIDS diseases in people on triple therapy
10. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine
11. Prise en charge des personnes atteintes par le VIH
12. Antiretroviral therapy for HIV infection in 1997
13. Does the covariance structure matter in longitudinal modelling for the prediction of future CD4 counts?
14. Modelling the relationship between survival after AIDS diagnosis and progression of markers of HIV disease
15. Regression models and life tables (with discussion)
16. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines
17. A new look at the statistical model identification
18. Modelling progression of CD4-lymphocyte count and its relationship to survival time
19. Models for empirical Bayes estimators of longitudinal CD4 counts
20. Longitudinal models for AIDS marker data
21. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: Implications for patient monitoring
22. HIV antivirals and immune recovery
23. Estimation and comparison of rates of change in longitudinal studies with informative drop-outs
24. Reconstitution and prediction of the HIV/ADS epidemic among adults in the European Union and in low prevalence countries of Central and Eastern Europe
25. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
26. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
27. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
28. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients
29. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by protease inhibitor indinavir
30. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen
31. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
32. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir
33. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA Study
34. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents
35. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
36. Opportunistic infections occurring during highly active antiretroviral treatment
37. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
38. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
39. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
40. Long-lasting recovery in CD4-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease